Pediatric anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: experience of a tertiary care teaching center from north India

J Child Neurol. 2014 Nov;29(11):1453-9. doi: 10.1177/0883073813494474. Epub 2013 Oct 4.

Abstract

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is characterized by acute- or subacute-onset encephalopathy with extrapyramidal, psychiatric, and epileptic manifestations. Diagnosis is confirmed by positive antibodies to NMDA receptor in cerebrospinal fluid and serum. Eleven pediatric cases presented over a 2-year period at a tertiary care teaching hospital in North India. The average age at presentation was 9 years (range: 2.5 to 18 years, median: 10 years) with a slight female predominance (1.2:1). The common modes of presentation were progressive extrapyramidal syndrome with global neuroregression in 45% (5 of 11), epileptiform encephalopathy in 27% (3 of 11), and an overlap between the 2 in 27% (3 of 11). Fifty-eight percent showed significant response to steroids and intravenous immunoglobulin. This entity should be considered in an acute- or subacute-onset encephalopathy if common infectious etiologies are ruled out and there are specific clinical pointers. Early diagnosis and treatment significantly improves the outcome.

Keywords: NMDA receptor; encephalitis; immunotherapy.

MeSH terms

  • Adolescent
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / diagnosis*
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / physiopathology
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / therapy*
  • Child
  • Child, Preschool
  • Early Diagnosis
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • India
  • Male
  • Retrospective Studies
  • Steroids / therapeutic use
  • Tertiary Healthcare
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Steroids